

AMENDED AND RESTATED FINAL TERMS DATED 2 November 2018

(amending and restating the final terms dated 05/03/2018)

SG ISSUER

Issue of Index Linked Leveraged Products

Unconditionally and irrevocably guaranteed by Société Générale

under the

Daily Leveraged Products Issuance Programme

PART A – CONTRACTUAL TERMS

Terms used herein shall be deemed to be defined as such for the purposes of the Terms and Conditions set forth under the heading "*Terms and Conditions of the English Law Leveraged Products*" in the base prospectus dated 27 October 2017 as supplemented by the supplements dated 30 November 2017, 18 January 2018 and 8 February 2018 (which constitutes a **Base Prospectus** for the purposes of article 5.4 of the Prospectus Directive 2003/71/EC) (the **Prospectus Directive**) as amended. This document constitutes the Final Terms of each Issue of Leveraged Products described herein for the purposes of Article 5.4 of the Prospectus Directive and Article 8.4 of the *loi luxembourgeoise relative aux prospectus pour valeurs mobilières* dated 10 July 2005, as amended, which implements the Prospectus Directive and must be read in conjunction with the Base Prospectus and each supplement thereto and any other supplement published prior to the Issue Date (as defined below) (**Supplement(s)**); provided, however, that to the extent such Supplement (i) is published after these Final Terms have been signed or issued and (ii) provides for any change to the Terms and Conditions as set out under the heading "*Terms and Conditions of the English Law Leveraged Products*", such change(s) shall have no effect with respect to the terms and conditions of the Leveraged Products to which these Final Terms relate. **Full information on the Issuer, the Guarantor and the offer of the Leveraged Products is only available on the basis of the combination of these Final Terms, the Base Prospectus and any Supplement(s).** Prior to acquiring an interest in the Leveraged Products described herein, prospective investors should read and understand the information provided in these Final Terms, the Base Prospectus and any Supplement(s) and be aware of the restrictions applicable to the offer and sale of such Leveraged Products in the United States or to, or for the account or benefit of, persons that are not Permitted Transferees.

A summary of the Leveraged Products (which comprises the summary in the Base Prospectus as amended to reflect the provisions of these Final Terms) is annexed to these Final Terms. Copies of the Base Prospectus, any Supplement(s) and these Final Terms are available for inspection from the head office of the Issuer, the Guarantor, the specified offices of the Paying Agents and, on the website of the Issuers (www.sglistedproducts.co.uk).

Any reference in these Final Terms to "General Terms and Conditions" is deemed to be a reference to "Terms and Conditions of the English Law Leveraged Products" when the governing law of the Leveraged Products is English law or "Terms and Conditions of the German Law Leveraged Products" when the governing law of the Leveraged Products is German law.

The Base Prospectus expires on 27 October 2018. The updated base prospectus and the subsequent base prospectuses will be available on the website(s) referred to above.

| | | |
|--|--|--|
| 1. | Security identification code(s): | |
| | ISIN code: | As specified in the "Annex for Multi-Series" attached hereto |
| | EPIC code: | As specified in the "Annex for Multi-Series" attached hereto |
| | SEDOL code: | As specified in the "Annex for Multi-Series" attached hereto |
| 2. | Date on which the Leveraged Products become fungible: | Not applicable |
| 3. | Issuance/Offer of Leveraged Products: | |
| - | Offered Amount of Leveraged Products: | As specified in the "Annex for Multi-Series" attached hereto |
| - | Issue Price: | As specified in the "Annex for Multi-Series" attached hereto |
| 4. | Issue Date: | 05/03/2018 |
| 5. | Expiration Date: | The Leveraged Products are Open-ended Leveraged Products. Condition 5.13 of the General Terms and Conditions applies. |
| 6. | Settlement Date: | The Leveraged Products are Open-ended Leveraged Products |
| 7. | (i) Status of Leveraged Products: | Secured. See paragraph 22 " <i>Secured Leveraged Products Provisions</i> " below. |
| | (ii) Type of Leveraged Products: | Notes as set out in condition 3.1 of the Terms and Conditions of the English Law Leveraged Products |
| | (iii) Type of Structured Leveraged Products: | The Leveraged Products are Index Linked Leveraged Products. The provisions of the following Additional Terms and Conditions apply: Additional Terms and Conditions for Index Linked Leveraged Products. |
| | (iv) Reference of the Product: | The Leveraged Products follow the condition 2.1 – Multiplicative Formula of the Additional Terms and Conditions relating to Formulae. The Leveraged Products are based on the 3.1 – Fixed Daily Leveraged Strategy Tracker with option Min/Max Restrike being applicable. |
| PROVISIONS RELATING TO AMOUNT(S) PAYABLE UNDER THE LEVERAGED PRODUCTS | | |
| 8. | Cash Settlement Amount: | Unless previously exercised or cancelled, each Leveraged Product shall entitle the Leveraged Product Holder to receive an amount on the Settlement Date equal to the Cash Settlement Amount, which is determined by the Calculation Agent as follow: |

| | | |
|--|--|--|
| | | Final Settlement Price |
| 9. | Final Settlement Price: | Unless previously exercised or cancelled in accordance with the Terms and Conditions, the Final Settlement Price for each Leveraged Product will be determined as follow: Final Settlement Price = Max(Initial Value x (FX(0) / FX(T)) x (LSL(T) / LSL(0)) x HedgingFeesFactor(T) ; 0) |
| | - Variable Data: | As set out in Condition 4.4.1. of the Additional Terms and Conditions relating to Formulae |
| | - Initial Value | As specified in the "Annex for Multi-Series" attached hereto |
| | - Applicable Rate: | As set out in Condition 4.6 of the Additional Terms and Conditions relating to Formulae |
| | %CommissionRate | As specified in the "Annex for Multi-Series" attached hereto |
| | %CollatCostRateInitial | As specified in the "Annex for Multi-Series" attached hereto |
| | %QuantoRate | 0% |
| | %Gap&ReplicationRateInitial | As specified in the "Annex for Multi-Series" attached hereto |
| 10. | Exercise Price: | Not applicable |
| 11. | Leverage | As specified in the "Annex for Multi-Series" attached hereto |
| 12. | Leveraged Strategy: | |
| | - Variable Data: | As set out in Condition 4.4.2. of the Additional Terms and Conditions relating to Formulae or as specified in the "Annex for Multi-Series" attached hereto |
| | DistRate | As specified in the "Annex for Multi-Series" attached hereto |
| | - Applicable Rate: | As set out in Condition 4.6 of the Additional Terms and Conditions relating to Formulae |
| PROVISIONS RELATING TO UNDERLYING | | |
| 13. | (i) Underlying: | The following Index as defined below: |
| | | As specified in the "Annex for Multi-Series" attached hereto |
| | (ii) Information relating to the past and future performances of the Underlying(s) and volatility: | The information relating to the past and future performances of the Underlying(s) and volatility are available on the source specified in the table annexed hereto. |
| | (iii) Provisions relating, amongst others, to the Market Disruption Event(s) and/or Disruption Event(s) and/or Extraordinary Event(s) and/or Monetisation until the | The provisions of the following Additional Terms and Conditions apply: Additional Terms and Conditions for Index Linked Leveraged Products |

| | | |
|---|---|--|
| | Expiration Date and/or any additional disruption event as described in the relevant Additional Terms and Conditions: | |
| | (iv) Other information relating to the Underlying(s): | Information or summaries of information included herein with respect to the Underlying(s), has been extracted from general databases released publicly or by any other available information. Each of the Issuer and the Guarantor confirms that such information has been accurately reproduced and that, so far as it is aware and is able to ascertain from information published, no facts have been omitted which would render the reproduced information inaccurate or misleading. |
| PROVISIONS RELATING TO DATES | | |
| 14. | Definitions relating to date(s): | Applicable |
| | Valuation Date(s) | As set out in Condition 4.5 of the Additional Terms and Conditions relating to Formulae |
| | Valuation Date (0) | 12/03/2018 |
| VI. EXERCISE AND SETTLEMENT PROVISIONS | | |
| 15. | Automatic Exercise: | Applicable |
| | - Event-linked Early Expiration: | Not applicable |
| 16. | Settlement Currency: | As specified in the "Annex for Multi-Series" attached hereto |
| 17. | Optional Early Expiration at the option of the Issuer: | Applicable as per Condition 5.6 of the General Terms and Conditions |
| | (i) Optional Early Settlement Amount: | Determined in accordance with Option 2 of Condition 5.6 of the General Terms and Conditions |
| | (ii) Optional Early Settlement Price: | Determined in accordance with Option 2 of Condition 5.6 of the General Terms and Conditions |
| | (iii) Optional Early Expiration in Part: | Not applicable |
| | (iv) Optional Early Settlement Valuation Date: | Means the third Valuation Date following the date of the notice by which the relevant Issuer has notified the Leveraged Product Holder that the relevant Issue of Leveraged Products will be subject to Early Expiration at the option of the Issuer in accordance with Condition 5.6 of the General Terms and Conditions |
| | (v) Notice Period: | Means the period starting on the date of the notice by which the relevant Issuer has notified the Leveraged Product Holder that the relevant Issue of Leveraged Products will be subject to Early Expiration at the option of the Issuer in accordance with Condition 5.6 of the General Terms and Conditions and ending on the Optional Early Expiration Date. |

| | | |
|------------|---|--|
| | (vi) Optional Early Expiration Date: | Means a date specified by the relevant Issuer in the notice given to the Leveraged Product Holder, which shall be not earlier than the fourth Valuation Date following the date of the notice by which the relevant Issuer has notified the Leveraged Product Holder that the relevant Issue of Leveraged Products will be subject to Early Expiration at the option of the Issuer in accordance with Condition 5.6 of the General Terms and Conditions. |
| | (vii) Optional Early Settlement Date: | The date falling on the sixth Business Day following the Optional Early Expiration Date |
| 18. | Optional Early Expiration at the option of the Leveraged Product Holder: | Applicable as per Condition 5.7 of the General Terms and Conditions |
| | (i) Optional Early Settlement Amount: | Determined in accordance with Option 2 of Condition 5.7 of the General Terms and Conditions where Optional Early Expiration Fee is set to up to 2% of the Optional Early Settlement Price as per Condition 5.7.1 of the General Terms and Conditions |
| | (ii) Optional Early Settlement Price: | Determined in accordance with Option 2 of Condition 5.7 of the General Terms and Conditions |
| | (iii) Optional Early Expiration in Part: | Applicable |
| | - Minimum Number of Leveraged Products subject to Optional Early Expiration at the option of the Leveraged Product Holder: | Not applicable |
| | - Maximum Number of Leveraged Products subject to Optional Early Expiration at the option of the Leveraged Product Holder: | Not applicable |
| | (iv) Optional Early Settlement Valuation Date: | Means the third Valuation Date following the date of the notice by which the relevant Leveraged Product Holder has notified the Issuer that the relevant Issue of Leveraged Products will be subject to Early Expiration at the option of the Leveraged Product Holder in accordance with Condition 5.7 of the General Terms and Conditions. |
| | (v) Notice Period: | Means the period starting on the date of the notice by which the relevant Leveraged Product Holder has notified the Issuer that the relevant Issue of Leveraged Products will be subject to Early Expiration at the option of the Leveraged Product Holder in accordance with Condition 5.7 of the General Terms and Conditions and ending on the Optional Early Expiration Date. |
| | (vi) Optional Early Expiration Date: | Means a date specified by the relevant Leveraged Product Holder in the notice given to the Issuer, which shall be not earlier than the fourth Valuation Date following the date of the notice by which the relevant Leveraged Product Holder has notified the Issuer that the relevant Issue of Leveraged Products will be subject to Early Expiration at the option of the Leveraged Product Holder in |

| | | |
|--|--|---|
| | | accordance with Condition 5.7 of the General Terms and Conditions. |
| | (vii) Optional Early Settlement Date: | The date falling on the sixth Business Day following the Optional Early Expiration Date |
| 19. | Trigger early settlement at the option of the Issuer | Not applicable |
| 20. | Cancellation for regulatory reasons and/or tax reasons and/or Force Majeure Event and/or at the option of the Calculation Agent pursuant to the relevant Additional Terms and Conditions: | Applicable as per Condition 5.2 and Condition 5.3 of the General Terms and Conditions and the Additional Terms and Conditions specified in paragraph 13 above (<i>Provisions relating, amongst others, to the Market Disruption Event(s) and/or Disruption Event(s) and/or Extraordinary Event(s) and/or Monetisation until the Expiration Date and/or any additional disruption event as described in the relevant Additional Terms and Conditions</i>) Condition 6.2 of the General Terms and Conditions will apply. |
| 21. | Provisions applicable to payment date(s): | |
| | - Payment Business Day: | Following Payment Business Day |
| | - Financial Centre(s): | As specified in the "Annex for Multi-Series" attached hereto |
| PROVISIONS RELATING TO SECURED LEVERAGED PRODUCTS | | |
| 22. | Secured Leveraged Product Provisions: | Applicable, subject to the provisions of the Additional Terms and Conditions relating to Secured Leveraged Products |
| | (i) Collateral Pool: | The Collateral Assets held in the Collateral Account N° 815969 established with the Collateral Custodian. |
| | (ii) Type of Collateral Pool: | Multiple Issue Collateral Pool |
| | (iii) Type of Collateralisation: | MV Collateralisation |
| | - Collateral Valuation at Nominal Value | Not applicable |
| | (iv) Eligibility Criteria: | Any assets that are eligible to be included in the assets of an Undertakings for Collective Investment in Transferable Securities complying with UCITS IV (being the Directive 2009/65/EC of the European Parliament and of the Council of 13 July 2009 on the coordination of laws, regulations and administrative provisions relating to undertakings for collective investment in transferable securities and as transposed under French law in the French "Code Monétaire et Financier" as applicable as of the Issue Date of the Leveraged Products). Bonds with a rating inferior to B ⁻ , asset backed securities (ABS) and non UCITS hedge funds shares are excluded from the scope of the Eligible Collateral Assets. The Collateral Assets that comply with the Eligibility Criteria will be referred to as the " Eligible Collateral Assets ". |

| | | |
|--|---|---|
| | (v) Collateral Rules: | The Eligible Collateral Assets shall meet the diversification requirements applying to the assets of an Undertaking for Collective Investment in Transferable Securities complying with UCITS IV. |
| | (vi) Collateralisation Percentage: | 100% |
| | (vii) Haircuts: | Applicable For equities other than any equities comprised in one of the following indices: S&P 500, EUROSTOXX 600, NIKKEI 225, HK Index, Korean Index, the applicable Haircut will be 10%. |
| | (viii) Collateral Test Dates: | Each Collateral Business Day |
| | (ix) Collateral Substitution: | Applicable |
| | (x) Waiver of Rights: | Applicable |
| | (xi) Early Termination Settlement Amount following the occurrence of a Collateral Disruption Event: | Market Value as per Condition 5.9 |
| | (xii) Order of Priority: | The Standard Order of Priority (as such term is defined in Condition 4.5 of the Additional Terms and Conditions relating to Secured Leveraged Products) applies |
| | (xiii) Other applicable options as per the Additional Terms and Conditions relating to Secured Leveraged Products: | Not applicable |
| GENERAL PROVISIONS RELATING TO LEVERAGED PRODUCTS | | |
| 23. | Reverse Split of Leveraged Products | Applicable as per Condition 5.4 of the General Terms and Conditions |
| | (i) Reverse Split Settlement Amount: | Market Value as per Condition 5.9 |
| | (ii) Reverse Split Notice Period: | At least 15 (fifteen) calendar days. |
| | (iii) Reverse Split Effective Date: | Means the date specified as such in the applicable Reverse Split Trigger Notice. |

| | | |
|------------|---|--|
| | (iv) Reverse Split Settlement Date: | Means the number of days or Business Days specified in the applicable Reverse Split Trigger Notice following the Reverse Split Effective Date. |
| 24. | Form of the Leveraged Products: | EUI Securities in book-entry form issued, cleared and settled through Euroclear UK & Ireland Limited (CREST). Direct CREST Settlement |
| 25. | Date of corporate authorisation obtained for the issuance of Leveraged Products: | Not applicable |

| | | |
|-----------|--|---|
| | PART B – OTHER INFORMATION | |
| 1. | LISTING AND ADMISSION TO TRADING | |
| | (i) Listing: | Application has been made for the Leveraged Products to be listed on the official list of the UK Listing Authority |
| | (ii) Admission to trading: | Application has been made for the Leveraged Products to be admitted to trading on the Regulated Market of the London Stock Exchange with effect from or as soon as practicable after the Issue Date. There can be no assurance that the listing and trading of the Leveraged Products will be approved with effect on the Issue Date or at all. |
| 2. | GOVERNING LAW | English law. |
| 3. | RATINGS | |
| | The Leveraged Products to be issued have not been rated. | |
| 4. | INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE ISSUE/OFFER | |
| | Save for any fees payable to the Dealer, so far as the Issuer is aware, no person involved in the issue of the Leveraged Products has an interest material to the offer. | |
| 5. | USE OF PROCEEDS, ESTIMATED NET PROCEEDS AND TOTAL EXPENSES | |
| | (i) Use of proceeds: | Not applicable |
| | (ii) Estimated net proceeds: | Not applicable |
| | (iii) Estimated total expenses: | Not applicable |
| 6. | PERFORMANCE OF FORMULA, EXPLANATION OF EFFECT ON VALUE OF INVESTMENT AND ASSOCIATED RISKS | |
| | <p>The value of Leveraged Products is significantly influenced by the price of the underlying. Therefore holders of the Leveraged Products have to consider the fact that with Leveraged Products they obtain a leveraged (long or short) exposure to the underlying and hence in a leveraged way bear the price risk of the underlying (downwards in the case of short Leveraged Products, upwards in the case of long Leveraged Products). As a result, prospective holders of Leveraged Products should evaluate the past, present and expected performance of the underlying while taking into account the expected future performance of the capital markets prior to the purchase of the Leveraged Products over their intended investment horizon.</p> <p>The factor leveraging the underlying operates both in positive and in negative price changes of the underlying: in the case of short Leveraged Products, holders are exposed to any increase in the price of the underlying while, in the case of long Leveraged Products, holders are exposed to any decrease in the price of the underlying. This, in both cases, would result in an amplified adverse performance of the Leveraged Products.</p> <p>Leveraged Products may include a regular restrike mechanism which may have adverse impacts on the performance of the Leveraged Products. Over time, this effect, known as “beta slippage” may result in a decline in the value of a Leveraged Product while the underlying would have moved favourably i.e. it is possible that, when observed over several days, the value of a long Leveraged Product decreases over</p> | |

| | | | |
|---|--|---|---|
| | <p>time despite the price or level of the underlying increasing over the same period of time (conversely it is possible that, when observed over several days, the value of a short Leveraged Product decreases over time despite the price or level of the underlying decreases over the same period of time).</p> <p>In addition to the regular restrike mechanism described above, Leveraged Products may include an intraday restrike mechanism. Although this mechanism aims to reduce the risk of the value of a Leveraged Product being equal to zero, there is no guarantee that this will be the case. In addition, certain intraday restrike mechanisms, especially the Min/Max restrike mechanism may result in a holder of a Leveraged Products incurring additional losses (including the total loss of their investment) and in preventing their Leveraged Products from recovering their value in case of subsequent market recovery (for long Leveraged Products) or decrease (for short Leveraged Products).</p> <p>Holders of Leveraged Products must be aware that the leverage mechanism embedded in Leveraged Products includes a certain number of fee and cost factors (for example and without limitation: financing of the leverage, borrowing cost for short Leveraged Products, costs to replicated and hedge the risk of the strategy underlying a Leveraged Product becoming negative) that are deducted on a regular basis from the value of the Leveraged Product. Therefore holders of Leveraged Products may face a loss despite the relevant underlying having posted a positive performance (for long Leveraged Products) or a negative performance (for short Leveraged Products).</p> <p>Holders of the Leveraged Products should also be aware that the Issuer may, at its discretion, perform reverse splits. In such case the number of Leveraged Products will be aggregated and these Leveraged Products will be converted into a smaller number of Leveraged Products calculated by dividing the number of pre-conversion Leveraged Products in by a predefined conversion factor. Although reverse splits are intended to provide additional liquidity to holders and to prevent the forced liquidation (and therefore complete exit) of a Leveraged Product, holders of Leveraged Products should be aware that (i) if such conversion entitles the holder to a fraction of a Leveraged Products such fraction will be settled in cash and that (ii) if a Leveraged Product benefits from an Absolute Floor, such Absolute Floor per Leveraged Product shall remain unaffected by the reverse split. As a result, any protection offered by an Absolute Floor will be greatly reduced by a reverse split.</p> | | |
| 7. | OPERATIONAL INFORMATION | | |
| | <table border="1"> <tr> <td data-bbox="337 1115 818 1178">(i) Other security identification code(s):</td> <td data-bbox="818 1115 1498 1178">Not applicable</td> </tr> </table> | (i) Other security identification code(s): | Not applicable |
| (i) Other security identification code(s): | Not applicable | | |
| | <table border="1"> <tr> <td data-bbox="337 1178 818 1297">(ii) Clearing System(s):</td> <td data-bbox="818 1178 1498 1297">Euroclear UK & Ireland Limited (CREST) 33 Cannon Street, London, EC4M 5SB, United Kingdom</td> </tr> </table> | (ii) Clearing System(s): | Euroclear UK & Ireland Limited (CREST) 33 Cannon Street, London, EC4M 5SB, United Kingdom |
| (ii) Clearing System(s): | Euroclear UK & Ireland Limited (CREST) 33 Cannon Street, London, EC4M 5SB, United Kingdom | | |
| | <table border="1"> <tr> <td data-bbox="337 1297 818 1360">(iii) Delivery:</td> <td data-bbox="818 1297 1498 1360">Delivery against payment</td> </tr> </table> | (iii) Delivery: | Delivery against payment |
| (iii) Delivery: | Delivery against payment | | |
| | <table border="1"> <tr> <td data-bbox="337 1360 818 1656">(iv) Calculation Agent:</td> <td data-bbox="818 1360 1498 1656">Société Générale Tour Société Générale 17 Cours Valmy 92987 Paris La Défense Cedex France</td> </tr> </table> | (iv) Calculation Agent: | Société Générale Tour Société Générale 17 Cours Valmy 92987 Paris La Défense Cedex France |
| (iv) Calculation Agent: | Société Générale Tour Société Générale 17 Cours Valmy 92987 Paris La Défense Cedex France | | |
| | <table border="1"> <tr> <td data-bbox="337 1656 818 1890">(v) Agent(s):</td> <td data-bbox="818 1656 1498 1890">EUI Agent: Computershare Investor Services (Jersey) Limited Queensway House, Hilgrove Street St Helier JE1 1ES, Jersey</td> </tr> </table> | (v) Agent(s): | EUI Agent: Computershare Investor Services (Jersey) Limited Queensway House, Hilgrove Street St Helier JE1 1ES, Jersey |
| (v) Agent(s): | EUI Agent: Computershare Investor Services (Jersey) Limited Queensway House, Hilgrove Street St Helier JE1 1ES, Jersey | | |

| | | |
|-----------|--|--|
| 8. | DISTRIBUTION | |
| | (i) Method of distribution: | Non-syndicated |
| | - Names and addresses and any underwriting commitment of the Dealer(s): | <p>Société Générale</p> <p>Tour Société Générale</p> <p>17 Cours Valmy</p> <p>92987 Paris La Défense Cedex</p> <p>France</p> <p>The Dealer will initially subscribe on the Issue Date for 100 per cent. of the Leveraged Products to be issued.</p> |
| | (ii) Total commission and concession: | There is no commission and/or concession paid by the Issuer to the Dealer |
| | (iii) TEFRA rules: | Not applicable |
| | (iv) Non-exempt Offer: | <p>Applicable</p> <p>A Non-exempt offer of the Leveraged Products may be made by the Dealer in the public offer jurisdiction(s) - the consent only extends to the use of this Base Prospectus to make Non-exempt Offers of the Leveraged Products in United Kingdom (Public Offer Jurisdiction(s)) during the offer period (Offer Period) as specified in the paragraph "Public Offers in European Economic Area" below.</p> |
| | (v) Individual Consent / Name(s) and address(es) of any Initial Authorised Offeror: | Not applicable |
| | (vi) General Consent/ Other conditions to consent: | Applicable |
| | (vii) U.S. federal income tax considerations | The Leveraged Products are not Specified Leveraged Products for purposes of Section 871(m) Regulations. |
| | (viii) Prohibition of Sales to EEA Retail Investors: | Not applicable |
| 9. | PUBLIC OFFERS IN EUROPEAN ECONOMIC AREA | |
| | - Public Offer Jurisdiction(s): | United Kingdom |
| | - Offer Period: | From 14 March 2018 to the date on which the Leveraged Products are delisted. |
| | - Offer Price: | The Leveraged Products will be offered at the market price which: |

| | | |
|------------|--|--|
| | | <ul style="list-style-type: none"> - will be determined by the Dealer on a daily basis in accordance with market conditions then prevailing including the current market price of the Underlying(s); and - will be provided by the Dealer to any Leveraged Product Holder upon request. |
| | - Conditions to which the offer is subject: | Not applicable |
| | - Description of the application process: | Not applicable |
| | - Details of the minimum and/or maximum amount of application: | 1 Leveraged Product |
| | - Details of the method and time limits for paying up and delivering the Leveraged Products: | The Leveraged Products will be issued on the Issue Date against payment to the Issuer of the net subscription moneys. The Leveraged Products will be delivered on any day during the offer by payment of the purchase price by the Leveraged Products Holders to the Dealer or the relevant financial intermediary. |
| | - Manner and date in which results of the offer are to be made public: | Publication on the website of the Issuer www.sglisterproducts.co.uk |
| | - Whether Issue(s) has/have been reserved for certain countries: | Not applicable |
| | - Process for notification to applicants of the amount allotted and the indication whether dealing may begin before notification is made: | Not applicable |
| | - Amount of any expenses and taxes specifically charged to the subscriber or purchaser: | Taxes charged in connection with the subscription, transfer, purchase or holding of the Leveraged Products must be paid by the Leveraged Products Holders and neither the Issuer nor the Guarantor shall have any obligation in relation thereto; in that respect, Leveraged Products Holders should consult professional tax advisers to determine the tax regime applicable to their own situation. The Leveraged Products Holders should also consult the Taxation section in the Base Prospectus |
| | - Name(s) and address(es), to the extent known to the Issuer, of the placers in the various countries where the offer takes place: | None |
| 10. | ADDITIONAL INFORMATION | |
| | - Minimum investment in the Leveraged Products: | One (1) Leveraged Product |
| | - Minimum trading number: | One (1) Leveraged Product |

ANNEX FOR MULTI-SERIES

(This Annex forms a part of the Final Terms to which it is attached)

| Issue | ISIN code | EPIC code | SEDOL code | Offered Amount of Leveraged Products* | Issue Price | Initial Value | Leverage | %Commission Rate | %Collateral CostRate Initial | %Gap & Replication Rate Initial | DistRate | Settlement Currency | Financial Centre |
|-------|--------------|-----------|------------|---------------------------------------|-------------|---------------|----------|------------------|------------------------------|---------------------------------|----------|---------------------|------------------|
| 1 | GB00BF9B3T84 | SG60 | BF9B3T8 | 100,000.00 | USD 100 | 100 | 1 | 0.90% | 0.05% | 0% | 0% | USD | New York |
| 2 | GB00BF9B3V07 | SG61 | BF9B3V0 | 100,000.00 | USD 100 | 100 | 1 | 0.90% | 0.05% | 0% | 0% | USD | New York |
| 3 | GB00BF9B3W14 | SG64 | BF9B3W1 | 100,000.00 | USD 100 | 100 | 1 | 0.90% | 0.05% | 0% | 0% | USD | New York |
| 4 | GB00BF9B3X21 | SG65 | BF9B3X2 | 100,000.00 | USD 100 | 100 | 1 | 0.90% | 0.05% | 0% | 0% | USD | New York |
| 5 | GB00BF9B3Y38 | SG68 | BF9B3Y3 | 100,000.00 | USD 100 | 100 | 1 | 0.90% | 0.05% | 0% | 0% | USD | New York |
| 6 | GB00BF9B3Z45 | SG69 | BF9B3Z4 | 100,000.00 | USD 100 | 100 | 1 | 0.90% | 0.05% | 0% | 0% | USD | New York |
| 7 | GB00BF9B5476 | SG66 | BF9B547 | 100,000.00 | USD 100 | 100 | 1 | 0.90% | 0.05% | 0% | 0% | USD | New York |
| 8 | GB00BF9B5583 | SG67 | BF9B558 | 100,000.00 | USD 100 | 100 | 1 | 0.90% | 0.05% | 0% | 0% | USD | New York |
| 9 | GB00BF9B5039 | SG58 | BF9B503 | 100,000.00 | USD 100 | 100 | 1 | 0.90% | 0.05% | 0% | 0% | USD | New York |
| 10 | GB00BF9B5146 | SG59 | BF9B514 | 100,000.00 | USD 100 | 100 | 1 | 0.90% | 0.05% | 0% | 0% | USD | New York |
| 11 | GB00BF9B5252 | SG62 | BF9B525 | 100,000.00 | USD 100 | 100 | 1 | 0.90% | 0.05% | 0% | 0% | USD | New York |
| 12 | GB00BF9B5369 | SG63 | BF9B536 | 100,000.00 | USD 100 | 100 | 1 | 0.90% | 0.05% | 0% | 0% | USD | New York |

| Issue | Name of Index | Bloomberg Ticker | Index Sponsor | ISIN code of the Index | Website |
|--------------|---|-------------------------|----------------------|-------------------------------|-------------------|
| 1 | Solactive x5 Daily Long EUR and Short USD Index | SOEUUS5L | Solactive AG | DE000SLA6RS6 | www.solactive.com |
| 2 | Solactive x5 Daily Short EUR and Long USD Index | SOEUUS5S | Solactive AG | DE000SLA6RU2 | www.solactive.com |
| 3 | Solactive x5 Daily Long GBP and Short USD Index | SOGBUS5L | Solactive AG | DE000SLA6R16 | www.solactive.com |
| 4 | Solactive x5 Daily Short GBP and Long USD Index | SOGBUS5S | Solactive AG | DE000SLA6R24 | www.solactive.com |
| 5 | Solactive x5 Daily Long JPY and Short USD Index | SOJPUS5L | Solactive AG | DE000SLA6RX6 | www.solactive.com |
| 6 | Solactive x5 Daily Short JPY and Long USD Index | SOJPUS5S | Solactive AG | DE000SLA6RY4 | www.solactive.com |
| 7 | Solactive x3 Daily Long JPY and Short USD Index | SOJPUS3L | Solactive AG | DE000SLA6RV0 | www.solactive.com |
| 8 | Solactive x3 Daily Short JPY and Long USD Index | SOJPUS3S | Solactive AG | DE000SLA6RW8 | www.solactive.com |
| 9 | Solactive X3 Daily Long EUR and Short USD Index | SOEUUS3L | Solactive AG | DE000SLA6RQ0 | www.solactive.com |
| 10 | Solactive X3 Daily Short EUR and Long USD Index | SOEUUS3S | Solactive AG | DE000SLA6RR8 | www.solactive.com |
| 11 | Solactive x3 Daily Long GBP and Short USD Index | SOGBUS3L | Solactive AG | DE000SLA6RZ1 | www.solactive.com |
| 12 | Solactive x3 Daily Short GBP and Long USD Index | SOGBUS3S | Solactive AG | DE000SLA6R08 | www.solactive.com |

ISSUE SPECIFIC SUMMARY

Summaries are made up of disclosure requirements known as *Elements* the communication of which is required by Annex XXII of the Commission Regulation (EC) No 809/2004 as amended. These elements are numbered in Sections – A – E (A.1 – E.7).

This summary contains all the *Elements* required to be included in a summary for this type of securities and Issuer. Because some *Elements* are not required to be addressed, there may be gaps in the numbering sequence of the *Elements*.

Even though an *Element* may be required to be inserted in the summary because of the type of securities and Issuer, it is possible that no relevant information can be given regarding the *Element*. In this case, a short description of the *Element* is included in the summary with the mention of "Not applicable".

| Section A – Introduction and warnings | | |
|---------------------------------------|--|--|
| A.1 | Warning | <p>This summary must be read as an introduction to the base prospectus.</p> <p>Any decision to invest in the leveraged products should be based on a consideration of the base prospectus as a whole by the investor.</p> <p>Where a claim relating to the information contained in the base prospectus and the applicable final terms is brought before a court, the plaintiff investor might, under the national legislation of the member states of the European Economic Area (the Member States), have to bear the costs of translating the base prospectus before the legal proceedings are initiated.</p> <p>Civil liability attaches only to those persons who have tabled this summary, including any translation thereof, but only if the summary is misleading, inaccurate or inconsistent when read together with the other parts of the base prospectus or it does not provide, when read together with the other parts of this base prospectus, key information in order to aid investors when considering whether to invest in the leveraged products.</p> |
| A.2 | Consent to the use of the Base Prospectus | <p>The Issuer consents to the use of this Base Prospectus in connection with a resale or placement of Leveraged Products in circumstances where a prospectus is required to be published under the Prospectus Directive (a Non-exempt Offer) subject to the following conditions:</p> <p>- the consent given by the Issuer for the use of the Base Prospectus to make the Non-exempt Offer is a general consent (a General Consent) in respect of any financial intermediary who published on its website that it will make the Non-exempt Offer of the Leveraged Products on the basis of the General Consent given by the Issuer and by such publication, any such financial intermediary (each a General Authorised Offeror) undertakes to comply with the following obligations:</p> <p>(a) it acts in accordance with all applicable laws, rules, regulations and guidance (including from any regulatory body) applicable to the Non-exempt Offer of the Leveraged Products in the Public Offer Jurisdiction, in particular the law implementing the Markets in Financial Instruments Directive (Directive 2004/39/EC) as amended (hereinafter the Rules) and makes sure that (i) any investment advice in the Leveraged Products by any person is appropriate, (ii) the information to prospective investors including the information relating to any expenses (and any commissions or benefits of any kind) received or paid by this General Authorised Offeror under the offer of the Leveraged Products is fully and clearly disclosed prior to their investment in the Leveraged Products;</p> <p>(b) it complies with the relevant subscription, sale and transfer restrictions related to the Public Offer Jurisdiction as if it acted as a Dealer in the Public Offer Jurisdiction;</p> |

(c) it ensures that the existence of any fee (and any other commissions or benefits of any kind) or rebate received or paid by it in relation to the offer or sale of the Leveraged Products does not violate the Rules is fully and clearly disclosed to investors or prospective investors prior to their investment in the Leveraged Products and to the extent required by the Rules, provides further information in respect thereof;

(d) it complies with the Rules relating to anti-money laundering, anti-corruption, anti-bribery and "know your customer" rules (including, without limitation, taking appropriate steps, in compliance with such rules, to establish and document the identity of each prospective investor prior to initial investment in any Leveraged Products by the investor), and will not permit any application for Leveraged Products in circumstances where it has any suspicion as to the source of the application monies; it retains investor identification records for at least the minimum period required under applicable Rules, and shall, if so requested, make such records available to the relevant Issuer and/or the relevant Dealer or directly to the competent authorities with jurisdiction over the relevant Issuer and/or the relevant Dealer in order to enable the relevant Issuer and/or the relevant Dealer to comply with anti-money laundering, anti-corruption, anti-bribery and "know your customer" rules applying to the relevant Issuer and/or the relevant Dealer;

(e) it co-operates with the Issuer and the relevant Dealer in providing relevant information (including, without limitation, documents and records maintained pursuant to paragraph (d) above) and such further assistance as reasonably requested upon written request from the Issuer or the relevant Dealer in each case, as soon as is reasonably practicable and, in any event, within any time frame set by any such regulator or regulatory process. For this purpose, relevant information that is available to or can be acquired by the relevant financial intermediary:

(i) in connection with any request or investigation by any regulator in relation to the Leveraged Products, the Issuer or the relevant Dealer; and/or

(ii) in connection with any complaints received by the Issuer and/or the relevant Dealer relating to the Issuer and/or the relevant Dealer or another Authorised Offeror including, without limitation, complaints as defined in rules published by any regulator of competent jurisdiction from time to time; and/or

(iii) which the Issuer or the relevant Dealer may reasonably require from time to time in relation to the Leveraged Products and/or as to allow the Issuer or the relevant Dealer fully to comply with its own legal, tax and regulatory requirements;

(f) it does not, directly or indirectly, cause the Issuer or the relevant Dealers to breach any Rule or any requirement to obtain or make any filing, authorisation or consent in any jurisdiction;

(g) it commits itself to indemnify the relevant Issuer, the Guarantor (if applicable) and the relevant Dealer, Société Générale and each of its affiliates for any damage, loss, expense, claim, request and fees (including reasonable fees from law firms) incurred by one of these entities because of, or in relation with, any failure by this General Authorised Offeror (or any of its sub-distributors) to respect any of these obligations above;

(h) it is familiar with, and has policies and procedures in place to comply with, any applicable rules and regulations relating to anti-bribery and corruption, including any changes thereto;

(i) (a) it and any person within its control (including any director, officer or employee, each a controlled person) has not committed and will not commit any corrupt act directly or indirectly and (b) to the best of its knowledge, none of its sub-distributors has committed any corrupt act directly or indirectly, in each case to or for the use or benefit of, any person or any government official (which shall include any official, employee or representative of, or any other person acting in an official capacity for or on behalf of any government of any jurisdiction, any public international organisation, any political party, or any quasi-governmental body);

(j) it has in place adequate policies, systems, procedures and controls designed to prevent itself, its sub-distributors and any controlled person from committing any corrupt act and to ensure that any evidence or suspicion of corrupt acts is fully investigated, reported to Société Générale or the relevant Issuer and acted upon accordingly;

(k) neither it nor any of its agents, sub-distributors or controlled persons is ineligible or treated by any governmental or international authority as ineligible to tender for any contract or business with, or to be awarded any contract or business by, such authority on the basis of any actual or alleged corrupt act;

(l) it has kept adequate records of its activities, including financial records in a form and manner appropriate for a business of its size and resources;

(m) it represents and warrants that it shall not distribute financial instruments to, or enter into any arrangement with respect to financial instruments with, sanctioned persons;

(n) it undertakes to promptly inform Société Générale or the relevant Issuer of (a) any complaint received in relation to its activities or the financial instruments; or (b) any event affecting it, including but not limited to any of: (i) a regulatory investigation or audit of it or its affiliates, partners or agents; (ii) legal proceedings initiated by a competent regulatory authority against it or its affiliates, partners or agents; or (iii) a judgment rendered or penalty levied against it or its affiliates, partners or agents, which in each case might reasonably involve a reputational risk for Société Générale or the relevant Issuer; and

(o) it acknowledges that its commitment to respect the obligations above is governed by English law and agrees that any related dispute be brought before the English courts.

Any General Authorised Offeror who wishes to use the Base Prospectus for an Non-exempt Offer of Leveraged Products in accordance with this General Consent and the related conditions is required, during the time of the relevant Offer Period, to publish on its website that it uses the Base Prospectus for such Non-exempt Offer in accordance with this General Consent and the related conditions.

- the consent only extends to the use of this Base Prospectus to make Non-exempt Offers of the Leveraged Products in United Kingdom.

The information relating to the conditions of the Non-exempt Offer shall be provided to the investors by any General Authorised Offeror at the time the offer is made.

| Section B – Issuer and Guarantor | | |
|----------------------------------|--|--|
| B.1 | Legal and commercial name of the issuer | SG Issuer (or the Issuer) |
| B.2 | Domicile, legal form, legislation and country of incorporation | Domicile: 33, boulevard Prince Henri, L-1724 Luxembourg. |

| | | Legal form: Public limited liability company (<i>société anonyme</i>). Legislation under which the Issuer operates: Luxembourg law. Country of incorporation: Luxembourg. | | | | | | | | | | | | | | | | | | | | | | | | | |
|--------------------------------------|--|--|---------------------------------|----------------------------------|----------------------------------|---------------------------------|----------------------------------|----------------------|---------|--------|--------|--------|--------------------------|-----|-----|-----|----|--------------------------------------|-----|----|-----|----|---------------------|------------|------------|------------|------------|
| B.4b | Known trends affecting the issuer and the industries in which it operates | The Issuer expects to continue its activity in accordance with its corporate objects over the course of 2017. | | | | | | | | | | | | | | | | | | | | | | | | | |
| B.5 | Description of the issuer's group and the issuer's position within the group | The Société Générale group (the Group) offers a wide range of advisory services and tailored financial solutions to individual customers, large corporate and institutional investors. The Group relies on three complementary core businesses: <ul style="list-style-type: none"> • French Retail Banking; • International Retail Banking, Financial Services and Insurance and • Corporate and Investment Banking, Private Banking, Asset and Wealth Management and Securities Services. The Issuer is a subsidiary of the Group and has no subsidiaries. | | | | | | | | | | | | | | | | | | | | | | | | | |
| B.9 | Figure of profit forecast or estimate of the issuer | Not applicable. The Issuer does not make any figure of profit forecast or estimate. | | | | | | | | | | | | | | | | | | | | | | | | | |
| B.10 | Nature of any qualifications in the audit report on the historical financial information | Not applicable. The audit report of the Issuer does not include any qualification. | | | | | | | | | | | | | | | | | | | | | | | | | |
| B.12 | Selected historical key financial information regarding the issuer | <table border="1"> <thead> <tr> <th>(in K€)</th> <th>Year ended 31.12.2015 (audited)</th> <th>Half year 30.06.2016 (unaudited)</th> <th>Year ended 31.12.2016 (audited)</th> <th>Half-year 30.06.2017 (unaudited)</th> </tr> </thead> <tbody> <tr> <td>Total Revenue</td> <td>102,968</td> <td>48,398</td> <td>90,991</td> <td>54,641</td> </tr> <tr> <td>Profit before tax</td> <td>380</td> <td>118</td> <td>525</td> <td>21</td> </tr> <tr> <td>Profit for the financial year</td> <td>380</td> <td>71</td> <td>373</td> <td>17</td> </tr> <tr> <td>Total Assets</td> <td>37,107,368</td> <td>44,984,808</td> <td>53,309,975</td> <td>52,864,508</td> </tr> </tbody> </table> | (in K€) | Year ended 31.12.2015 (audited) | Half year 30.06.2016 (unaudited) | Year ended 31.12.2016 (audited) | Half-year 30.06.2017 (unaudited) | Total Revenue | 102,968 | 48,398 | 90,991 | 54,641 | Profit before tax | 380 | 118 | 525 | 21 | Profit for the financial year | 380 | 71 | 373 | 17 | Total Assets | 37,107,368 | 44,984,808 | 53,309,975 | 52,864,508 |
| (in K€) | Year ended 31.12.2015 (audited) | Half year 30.06.2016 (unaudited) | Year ended 31.12.2016 (audited) | Half-year 30.06.2017 (unaudited) | | | | | | | | | | | | | | | | | | | | | | | |
| Total Revenue | 102,968 | 48,398 | 90,991 | 54,641 | | | | | | | | | | | | | | | | | | | | | | | |
| Profit before tax | 380 | 118 | 525 | 21 | | | | | | | | | | | | | | | | | | | | | | | |
| Profit for the financial year | 380 | 71 | 373 | 17 | | | | | | | | | | | | | | | | | | | | | | | |
| Total Assets | 37,107,368 | 44,984,808 | 53,309,975 | 52,864,508 | | | | | | | | | | | | | | | | | | | | | | | |
| | Statement that there has been no material adverse change in the prospects of the issuer since the date of its last published audited financial statements | There has been no material adverse change in the prospects of the Issuer since 31 December 2016. | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Significant changes in the issuer's financial or trading position subsequent to the period covered by the historical financial information | Not applicable. There has been no significant change in the financial or trading position of the Issuer since 30 June 2016. | | | | | | | | | | | | | | | | | | | | | | | | | |
| B.13 | Recent events particular to the issuer which are to a material extent relevant to the evaluation of the issuer's solvency | Not applicable. There has been no recent event particular to the Issuer which is to a material extent relevant to the evaluation of the Issuer's solvency. | | | | | | | | | | | | | | | | | | | | | | | | | |

| | | |
|-------------|---|--|
| B.14 | Statement as to whether the issuer is dependent upon other entities within the group | See Element B.5 above for the Issuers' position within the Group. SG Issuer is dependent upon Société Générale Bank & Trust within the Group. |
| B.15 | Description of the Issuer's principal activities | The principal activity of SG Issuer is raising finance by the issuance of leveraged products as well as debt securities designed to be placed to institutional customers or retail customers through the distributors associated with Société Générale. The financing obtained through the issuance of such debt securities is then lent to Société Générale and to other members of the Group. |
| B.16 | To the extent known to the issuer, whether the issuer is directly or indirectly owned or controlled and by whom, and description of the nature of such control | SG Issuer is a 100 per cent. owned subsidiary of Société Générale Bank & Trust S.A. which is itself a 100 per cent, owned subsidiary of Société Générale and is a fully consolidated company. |
| B.18 | Nature and scope of the guarantee | <p>The Leveraged Products are unconditionally and irrevocably guaranteed by Société Générale (the Guarantor) pursuant to the guarantee made as of 14 September 2017 (the Guarantee).</p> <p>The Guarantee constitutes a direct, unconditional, unsecured and general obligation of the Guarantor and ranks and will rank at least <i>pari passu</i> with all other existing and future direct, unconditional, unsecured and general obligations of the Guarantor, including those in respect of deposits.</p> <p>Any references to sums or amounts payable by the Issuer which are guaranteed by the Guarantor under the Guarantee shall be to such sums and/or amounts as directly reduced, and/or in the case of conversion into equity, as reduced by the amount of such conversion, and/or otherwise modified from time to time resulting from the application of a bail-in power by any relevant authority pursuant to directive 2014/59/EU of the European Parliament and of the Council of the European Union.</p> |
| B.19 | Information about the guarantor as if it were the issuer of the same type of security that is subject of the guarantee | <p>The information about Société Générale as if it were the Issuer of the same type of Leveraged Products that is subject of the Guarantee is set out in accordance with Elements B.19 / B.1, B.19 / B.2, B.19 / B.4b, B.19 / B.5, B.19 / B.9, B.19 / B.10, B.19 / B.12, B.19 / B.13, B.19 / B.14, B.19 / B.15 and B.19 / B.16 below, respectively:</p> <p>B.19/ B.1: Legal and commercial name of the guarantor Société Générale</p> <p>B.19/ B.2: Domicile, legal form, legislation and country of incorporation Domicile: 29, boulevard Haussmann, 75009 Paris, France. Legal form: Public limited liability company (société anonyme). Legislation under which the Issuer operates: French law. Country of incorporation: France.</p> <p>B.19/ B.4b: Known trends affecting the guarantor and the industries in which it operates Société Générale continues to be subject to the usual risks and the risks inherent in its business mentioned in Chapter 4 of the Registration Document filed on 8 March 2017, and in its updated version filed on 4 May 2017.</p> <p>In a context of firming world growth, several risks continue to weigh on global economic prospects: risks of renewed financial tensions in Europe,</p> |

| | | | | (audited, except mentioned otherwise*) |
|---|---------|---------|---------|--|
| Results (in millions of euros) | | | | |
| Net Banking Income | 17,631 | 25,298 | 19,169 | 25,639 |
| Operating income | 3,937 | 6,390 | 5,145 | 5,681 |
| Net income | 3,191 | 4,338 | 3,835 | 4,395 |
| Reported Group Net income | 2,737 | 3,874 | 3,484 | 4,001 |
| <i>French retail Banking</i> | 988 | 1,486 | 1,084 | 1,441* |
| <i>International Retail Banking & Financial Services</i> | 1,501 | 1,631 | 1,193 | 1,111* |
| <i>Global Banking and Investor Solutions</i> | 1,198 | 1,803 | 1,371 | 1,850* |
| <i>Corporate Centre</i> | (950) | (1,046) | (164) | (401)* |
| Net cost of risk | (880) | (2,091) | (1,605) | (3,065) |
| Activity (in billions of euros) | | | | |
| Total assets and liabilities | 1,338.7 | 1,382.2 | 1,404.9 | 1,334.4 |
| Customer loans | 412.2 | 426.5 | 423.1 | 405.3 |
| Customer deposits | 396.7 | 421.0 | 406.0 | 379.6 |
| Equity (in billions of euros) | | | | |
| Group shareholders' equity | 60.3 | 62.0 | 60.9 | 59.0 |
| Non-controlling Interests | 4.5 | 3.8 | 3.7 | 3.6 |
| Cash flow statements (in millions of euros) | | | | |
| Net inflow (outflow) in cash and cash equivalent | - | 18,442 | - | 21,492 |
| <p>(*)Amounts restated (unaudited) relative to the financial statements published at 31 December 2015 due to adjustments of normative capital calculation method within business lines</p> <p>Statement as no material adverse change in the prospects of the guarantor since the date of its last published audited financial statements:</p> <p>There has been no material adverse change in the prospects of Société Générale since 31 December 2016.</p> <p>Significant changes in the guarantor's financial or trading position subsequent to the period covered by the historical financial information:</p> <p>Not applicable. There has been no significant change in the financial or trading position of Société Générale since 30 September 2017.</p> <p>B.19/ B.13: Recent events particular to the guarantor which are to a material extent relevant to the evaluation of the guarantor's solvency</p> <p>Not applicable. There has been no recent event particular to Société Générale which is to a material extent relevant to the evaluation of its solvency.</p> <p>B.19/ B.14: Statement as to whether the guarantor is dependent upon other entities within the group</p> | | | | |

See Element B.5 above for the Société Générale's position within the Group.

Société Générale is the ultimate holding company of the Group. However, Société Générale operates its own business; it does not act as a simple holding company vis-à-vis its subsidiaries.

B.19/ B.15: Description of the guarantor's principal activities

See Element B.19/B.5 above

B.19/ B.16: To the extent known to the guarantor, whether the guarantor is directly or indirectly owned or controlled and by whom, and description of the nature of such control

Not applicable. To its knowledge, Société Générale is not owned or controlled, directly or indirectly (under French law) by another entity.

Section C – Securities

| C.1 | Type and class of the securities being offered and/or admitted to trading, including any security identification number | <p>The Leveraged Products are linked to indices (the Leveraged Products).</p> <p>The English Law Leveraged Products are issued as notes.</p> <p>ISIN code of the Leveraged Products: See table below.</p> <p>EPIC code of the Leveraged Products: See table below.</p> <p>SEDOL code of the Leveraged Products: See table below.</p> <table border="1" data-bbox="428 1031 1029 1480"> <thead> <tr> <th>Issue</th> <th>ISIN code</th> <th>EPIC code</th> <th>SEDOL code</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>GB00BF9B3T84</td> <td>SG60</td> <td>BF9B3T8</td> </tr> <tr> <td>2</td> <td>GB00BF9B3V07</td> <td>SG61</td> <td>BF9B3V0</td> </tr> <tr> <td>3</td> <td>GB00BF9B3W14</td> <td>SG64</td> <td>BF9B3W1</td> </tr> <tr> <td>4</td> <td>GB00BF9B3X21</td> <td>SG65</td> <td>BF9B3X2</td> </tr> <tr> <td>5</td> <td>GB00BF9B3Y38</td> <td>SG68</td> <td>BF9B3Y3</td> </tr> <tr> <td>6</td> <td>GB00BF9B3Z45</td> <td>SG69</td> <td>BF9B3Z4</td> </tr> <tr> <td>7</td> <td>GB00BF9B5476</td> <td>SG66</td> <td>BF9B547</td> </tr> <tr> <td>8</td> <td>GB00BF9B5583</td> <td>SG67</td> <td>BF9B558</td> </tr> <tr> <td>9</td> <td>GB00BF9B5039</td> <td>SG58</td> <td>BF9B503</td> </tr> <tr> <td>10</td> <td>GB00BF9B5146</td> <td>SG59</td> <td>BF9B514</td> </tr> <tr> <td>11</td> <td>GB00BF9B5252</td> <td>SG62</td> <td>BF9B525</td> </tr> <tr> <td>12</td> <td>GB00BF9B5369</td> <td>SG63</td> <td>BF9B536</td> </tr> </tbody> </table> | Issue | ISIN code | EPIC code | SEDOL code | 1 | GB00BF9B3T84 | SG60 | BF9B3T8 | 2 | GB00BF9B3V07 | SG61 | BF9B3V0 | 3 | GB00BF9B3W14 | SG64 | BF9B3W1 | 4 | GB00BF9B3X21 | SG65 | BF9B3X2 | 5 | GB00BF9B3Y38 | SG68 | BF9B3Y3 | 6 | GB00BF9B3Z45 | SG69 | BF9B3Z4 | 7 | GB00BF9B5476 | SG66 | BF9B547 | 8 | GB00BF9B5583 | SG67 | BF9B558 | 9 | GB00BF9B5039 | SG58 | BF9B503 | 10 | GB00BF9B5146 | SG59 | BF9B514 | 11 | GB00BF9B5252 | SG62 | BF9B525 | 12 | GB00BF9B5369 | SG63 | BF9B536 |
|-------|---|---|------------|-----------|-----------|------------|---|--------------|------|---------|---|--------------|------|---------|---|--------------|------|---------|---|--------------|------|---------|---|--------------|------|---------|---|--------------|------|---------|---|--------------|------|---------|---|--------------|------|---------|---|--------------|------|---------|----|--------------|------|---------|----|--------------|------|---------|----|--------------|------|---------|
| Issue | ISIN code | EPIC code | SEDOL code | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | GB00BF9B3T84 | SG60 | BF9B3T8 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | GB00BF9B3V07 | SG61 | BF9B3V0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | GB00BF9B3W14 | SG64 | BF9B3W1 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4 | GB00BF9B3X21 | SG65 | BF9B3X2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 5 | GB00BF9B3Y38 | SG68 | BF9B3Y3 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6 | GB00BF9B3Z45 | SG69 | BF9B3Z4 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 7 | GB00BF9B5476 | SG66 | BF9B547 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 8 | GB00BF9B5583 | SG67 | BF9B558 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 9 | GB00BF9B5039 | SG58 | BF9B503 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10 | GB00BF9B5146 | SG59 | BF9B514 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 11 | GB00BF9B5252 | SG62 | BF9B525 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 12 | GB00BF9B5369 | SG63 | BF9B536 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| C.2 | Currency of the securities issue | USD | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| C.5 | Description of any restrictions on the free transferability of the securities | <p>Not applicable. There is no restriction on the free transferability of the Leveraged Products, subject to selling and transfer restrictions which may apply in certain jurisdictions including restrictions applicable to the offer and sale to, or for the account or benefit of, Permitted Transferees.</p> <p>A Permitted Transferee means any person who (i) is not a U.S. person as defined pursuant to Regulation S; and (ii) is not a person who comes within any definition of U.S. person for the purposes of the CEA or any CFTC Rule, guidance or order proposed or issued under the CEA.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| | | | | | | |
|------------------------------|---|--|------------------------------|---|--------------------------|--|
| C.8 | Rights attached to the securities, including ranking and limitations to those rights | <p>Rights attached to the securities:</p> <p>Unless the Leveraged Products are previously cancelled or otherwise expire early, the Leveraged Products will entitle each holder of the Leveraged Products (a Leveraged Product Holder) to receive a redemption amount which may be lower than, equal to or higher than the amount initially invested (see Element C.18).</p> <p>In addition to the Guarantees of the Guarantor, payments due under the Leveraged Products will be secured by a pledge over collateral assets which comply with the following Eligibility Criteria and Collateral Rules:</p> <table border="1" data-bbox="430 541 1382 1367"> <tr> <td data-bbox="430 541 824 1220"> Eligibility Criteria: </td> <td data-bbox="824 541 1382 1220"> <p>Any assets that are eligible to be included in the assets of an Undertakings for Collective Investment in Transferable Securities complying with UCITS IV (being the Directive 2009/65/EC of the European Parliament and of the Council of 13 July 2009 on the coordination of laws, regulations and administrative provisions relating to undertakings for collective investment in transferable securities and as transposed under French law in the French “Code Monétaire et Financier” as applicable as of the Issue Date of the Leveraged Products).</p> <p>Bonds with a rating inferior to B-, asset backed securities (ABS) and non UCITS hedge funds shares are excluded from the scope of the Eligible Collateral Assets.</p> <p>The Collateral Assets that comply with the Eligibility Criteria will be referred to as the “Eligible Collateral Assets”.</p> </td> </tr> <tr> <td data-bbox="430 1220 824 1367"> Collateral Rules: </td> <td data-bbox="824 1220 1382 1367"> <p>The Eligible Collateral Assets shall meet the diversification requirements applying to the assets of an Undertaking for Collective Investment in Transferable Securities complying with UCITS IV.</p> </td> </tr> </table> <p>A Leveraged Product Holder will be entitled to claim the immediate and due payment of any sums if:</p> <ul style="list-style-type: none"> - the Issuer fails to pay or to perform its other obligations under the Leveraged Products including its obligations under the pledge securing the Leveraged Products; - the Guarantor fails to perform its obligations under the Guarantees or in the event that the guarantees of the Guarantor stop being valid; - there are insolvency or bankruptcy proceeding(s) affecting the Issuer; - the collateral monitoring agent in respect of the Leveraged Products delivers a default notice in respect of the collateral pool securing the Leveraged Products; or | Eligibility Criteria: | <p>Any assets that are eligible to be included in the assets of an Undertakings for Collective Investment in Transferable Securities complying with UCITS IV (being the Directive 2009/65/EC of the European Parliament and of the Council of 13 July 2009 on the coordination of laws, regulations and administrative provisions relating to undertakings for collective investment in transferable securities and as transposed under French law in the French “Code Monétaire et Financier” as applicable as of the Issue Date of the Leveraged Products).</p> <p>Bonds with a rating inferior to B-, asset backed securities (ABS) and non UCITS hedge funds shares are excluded from the scope of the Eligible Collateral Assets.</p> <p>The Collateral Assets that comply with the Eligibility Criteria will be referred to as the “Eligible Collateral Assets”.</p> | Collateral Rules: | <p>The Eligible Collateral Assets shall meet the diversification requirements applying to the assets of an Undertaking for Collective Investment in Transferable Securities complying with UCITS IV.</p> |
| Eligibility Criteria: | <p>Any assets that are eligible to be included in the assets of an Undertakings for Collective Investment in Transferable Securities complying with UCITS IV (being the Directive 2009/65/EC of the European Parliament and of the Council of 13 July 2009 on the coordination of laws, regulations and administrative provisions relating to undertakings for collective investment in transferable securities and as transposed under French law in the French “Code Monétaire et Financier” as applicable as of the Issue Date of the Leveraged Products).</p> <p>Bonds with a rating inferior to B-, asset backed securities (ABS) and non UCITS hedge funds shares are excluded from the scope of the Eligible Collateral Assets.</p> <p>The Collateral Assets that comply with the Eligibility Criteria will be referred to as the “Eligible Collateral Assets”.</p> | | | | | |
| Collateral Rules: | <p>The Eligible Collateral Assets shall meet the diversification requirements applying to the assets of an Undertaking for Collective Investment in Transferable Securities complying with UCITS IV.</p> | | | | | |

- an event of the type described above occurs in respect of any other issue of leveraged products which is secured by the same collateral pool in respect of which the Leveraged Products are secured, the holder of any Leveraged Product may cause the Leveraged Products to be cancelled immediately and for the payment of an early termination settlement amount to become due to the Leveraged Product Holder.

The Leveraged Product Holder may cancel or otherwise cause the Leveraged Products to expire early.

The Leveraged Product Holders' consent shall have to be obtained to amend the contractual terms of the Leveraged Products (except where the amendment is (i) to cure or correct any ambiguity or defective or inconsistent provision contained therein, or which is of a formal, minor or technical nature or (ii) not prejudicial to the interests of the Leveraged Product Holders or (iii) to correct a manifest error or proven error or (iv) to comply with mandatory provisions of the law) pursuant to the provisions of an agency agreement, made available to the Leveraged Product Holders upon request to the Issuer.

Waiver of Set-off rights

The Leveraged Product Holder waive any right of set-off, compensation and retention in relation to the Leveraged Product, to the extent permitted by law.

Governing law

The Leveraged Products and any non-contractual obligations arising out of or in connection with the Leveraged Products will be governed by, and shall be construed in accordance with English law.

The Issuer accepts the competence of the courts of England in relation to any dispute against the Issuer but accepts that such Leveraged Product Holders may bring their action before any other competent court.

Ranking:

The Leveraged Products will be direct, unconditional, unsecured and unsubordinated obligations of the Issuer and will rank at least *pari passu* with all other outstanding direct, unconditional, unsecured and unsubordinated obligations of the Issuer, present and future.

Limitations to rights attached to the securities:

- The Issuer may adjust the financial terms in case of adjustment events affecting the underlying instrument(s), and in the case of the occurrence of extraordinary events affecting the underlying instrument(s), and/or in circumstances where Société Générale and any of its affiliates' aggregate interest in the underlying instrument(s) exceeds certain limits, the Issuer may substitute the underlying instrument(s) by new underlying instrument(s), or deduct from any due amount the increased cost of hedging, and in each case without the consent of the Leveraged Product Holders;

- The Issuer may cancel or otherwise early expire the Leveraged Products on the basis of the market value of these Leveraged Products in case of occurrence of a collateral disruption event;

- The Issuer may cancel or otherwise early expire the Leveraged Products on the basis of the market value of these Leveraged Products, monetise all or part of the due amounts until the expiration date of the Leveraged Products for tax or regulatory reasons or in the case of occurrence of extraordinary events affecting the underlying or in the case of occurrence of adjustments affecting the underlying instrument(s);

| | | |
|----------|---|--|
| | | <p>- the rights to payment of any amounts due under the Leveraged Products will be prescribed within a period of ten years from the date on which the payment of such amounts has become due for the first time and has remained unpaid;</p> <p>- in the case of a payment default under the Secured Leveraged Products issued by SG Issuer or the Guarantor, Leveraged Product Holders' recourse against the security trustee under the pledge agreement will be limited to the collateral assets applicable to the Issue of Leveraged Products, constituting together the collateral pool, which is a multiple issue collateral pool and then may be shared by several issues of secured leveraged products. Nevertheless, Leveraged Product Holders will continue to be able to claim against the Guarantor in respect of any unpaid amount; and</p> <p>in the case of a payment default by the Issuer, Leveraged Product Holders shall not institute any proceedings, judicial or otherwise, or otherwise assert a claim against the Issuer. Nevertheless, Leveraged Product Holders will continue to be able to claim against the Guarantor in respect of any unpaid amount.</p> <p>Taxation</p> <p>All payments in respect of Leveraged Products or under the Guarantees shall be made free and clear of, and without withholding or deduction for or on account of, any present or future taxes, duties, assessments or governmental charges of whatever nature imposed, levied, collected, withheld or assessed by or on behalf of any Tax Jurisdiction unless such withholding or deduction is required by law.</p> <p>In the event that any amounts are required to be deducted or withheld for, or on behalf of, any Tax Jurisdiction, the relevant Issuer or, as the case may be, the Guarantor shall (except in certain circumstances), to the fullest extent permitted by law, pay such additional amount as may be necessary, in order that each Leveraged Product Holder, after such deduction or withholding, will receive the full amount then due and payable.</p> <p>Where:</p> <p>Tax Jurisdiction means Luxembourg or any political subdivision or any authority thereof or therein having power to tax.</p> |
| C.1 1 | <p>Whether the securities offered are or will be the object of an application for admission to trading, with a view to their distribution in a regulated market or other equivalent markets with indication of</p> | <p>Application has been made for the Leveraged Products to be admitted to trading on the regulated market of London Stock Exchange</p> |

| | | |
|-------|--|---|
| | the markets in question | |
| C.1 5 | How the value of the investment is affected by the value of the underlying instrument(s) | <p>The value of the Leveraged Products and the payment of a settlement amount to a Leveraged Product Holder will depend on the performance of the Leveraged Strategy, on the relevant valuation date(s).</p> <p>The Leveraged Products provide exposure to the performance (either positive or negative) of a Leveraged Strategy. The leverage embedded in the leveraged strategy amplifies the positive or negative exposure to the underlying to which such Leveraged Strategy relates.</p> |
| C.1 6 | The maturity date and the final reference date | Not applicable. The Leveraged Products are open-ended Leveraged Products. No final reference date is applicable to the Leveraged Products |
| C.1 7 | Settlement procedure of the derivative securities | Cash delivery |
| C.1 8 | How the return on derivative securities takes place | <p>Subject as provided below, the Leveraged Products will be settled in cash (Cash Settled Leveraged Products).</p> <p>The leveraged products are open-ended Leveraged Products and do not have a fixed expiry date. The Issuer will therefore only be liable in respect of the exercise of each Leveraged Product, to pay or procure payment of an early settlement amount as described below.</p> <p>The Cash Settlement Amount is an amount equal to the Final Settlement Price</p> <p>where</p> <p>the Final Settlement Price is $\text{Max}(\text{Initial Value} \times (\text{FX}(0) / \text{FX}(T)) \times ((\text{LSL}(T) / \text{LSL}(0)) \times \text{HedgingFeesFactor}(T); 0)$</p> <p>Valuation Date(0) means 12/03/2018.</p> <p>Valuation Date(i) means, for each $i \geq 1$, any scheduled trading day following Valuation Date (0) (excluded) until the earlier of the Optional Early Settlement Valuation Date.</p> <p>In each case such a Valuation Date (i) is scheduled trading day immediately following Valuation Date (i-1).</p> <p>Final Valuation Date or Valuation Date(T) means the Optional Early Settlement Valuation Date.</p> <p>Issue Date means 05/03/2018</p> <p>Optional Early Settlement Valuation Date means the third scheduled trading day following the exercise by the Issuer or the Leveraged Product Holder of the option to early terminate the Leveraged Products.</p> <p>The Leveraged Products may be exercised early at the option of the Issuer or the Leveraged Product Holders.</p> <p>Leveraged Product Holders shall be entitled in such circumstances to the Optional Early Settlement Amount which shall be an amount determined in the same manner as the Cash Settlement Amount would have been determined save that the "Final Settlement Price" will be deemed to be the Optional Early Settlement Price where</p> |

Optional Early Settlement Price = $\text{Max}(\text{Initial Value} \times (\text{FX}(0) / \text{FX}(T)) \times ((\text{LSL}(T) / \text{LSL}(0)) \times \text{HedgingFeesFactor}(T)); 0)$

where T is the Final Valuation Date.

Where the Issuer and a Leveraged Product Holder does not elect that the Leveraged Products will be subject to early expiration at the option of the Issuer or Leveraged Product Holders, the Leveraged Products shall remain subject to exercise or cancellation in accordance with the terms and conditions of the Leveraged Product.

Variable Data relating to the determination of the Product Formula

Initial Value

As specified in the table below.

Leverage

As specified in the table below.

Applicable Rates:

%CommissionRate

As specified in the table below.

%CollatCostRateInitial

As specified in the table below.

%QuantoRate

means 0%

%Gap&ReplicationRateInitial

As specified in the table below.

Variable Data relating to the determination of the Leveraged Strategy

DistRate

As specified in the table below.

Table:

| Issue | Initial Value | Leverage | %CommissionRate | %Collat CostRateInitial | %Gap&ReplicationRateInitial | DistRate |
|-------|---------------|----------|-----------------|-------------------------|-----------------------------|----------|
| 1 | 100 | 1 | 0.90% | 0.05% | 0% | 0% |
| 2 | 100 | 1 | 0.90% | 0.05% | 0% | 0% |
| 3 | 100 | 1 | 0.90% | 0.05% | 0% | 0% |
| 4 | 100 | 1 | 0.90% | 0.05% | 0% | 0% |
| 5 | 100 | 1 | 0.90% | 0.05% | 0% | 0% |
| 6 | 100 | 1 | 0.90% | 0.05% | 0% | 0% |
| 7 | 100 | 1 | 0.90% | 0.05% | 0% | 0% |
| 8 | 100 | 1 | 0.90% | 0.05% | 0% | 0% |
| 9 | 100 | 1 | 0.90% | 0.05% | 0% | 0% |
| 10 | 100 | 1 | 0.90% | 0.05% | 0% | 0% |
| 11 | 100 | 1 | 0.90% | 0.05% | 0% | 0% |
| 12 | 100 | 1 | 0.90% | 0.05% | 0% | 0% |

| | | <p>* means a rate determined by the Calculation Agent as the percentage of Dist(i) that would be received by a hypothetical investor located in Luxembourg, net of any withholding tax, before application of any tax credit and assuming that such hypothetical investor does not benefit from double taxation treaties.</p> <p>Dist(i) means Dist(i1;i2), where Dist(i1;i2) means, for any dates (i1) and (i2), the sum of all Gross Ordinary Distributions, paid in respect of the Underlying, which have an ex date between (i1) (excluded) and (i2) (included).</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-------------|--|---|---------------|------------------------|--|---------------|------------------------|---------|---|---|----------|--------------|--------------|--|---|---|----------|--------------|--------------|--|---|---|----------|--------------|--------------|--|---|---|----------|--------------|--------------|--|---|---|----------|--------------|--------------|--|---|---|----------|--------------|--------------|--|---|---|----------|--------------|--------------|--|---|---|----------|--------------|--------------|--|---|---|----------|--------------|--------------|--|
| C.19 | The final reference price of the underlying | See Element C.18 above. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| C.20 | Type of the underlying and where the information on the underlying can be found | <p>The Leveraged Products are linked to the following underlying indices.</p> <p>Information about the underlying is available on the following website(s) or screen page(s):</p> <table border="1"> <thead> <tr> <th>Issue</th> <th>Name of Index</th> <th>Bloomberg Ticker</th> <th>Index Sponsor</th> <th>ISIN code of the Index</th> <th>Website</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Solactive x5 Daily Long EUR and Short USD Index</td> <td>SOEUUS5L</td> <td>Solactive AG</td> <td>DE000SLA6RS6</td> <td>www.solactive.com</td> </tr> <tr> <td>2</td> <td>Solactive x5 Daily Short EUR and Long USD Index</td> <td>SOEUUS5S</td> <td>Solactive AG</td> <td>DE000SLA6RU2</td> <td>www.solactive.com</td> </tr> <tr> <td>3</td> <td>Solactive x5 Daily Long GBP and Short USD Index</td> <td>SOGBUS5L</td> <td>Solactive AG</td> <td>DE000SLA6R16</td> <td>www.solactive.com</td> </tr> <tr> <td>4</td> <td>Solactive x5 Daily Short GBP and Long USD Index</td> <td>SOGBUS5S</td> <td>Solactive AG</td> <td>DE000SLA6R24</td> <td>www.solactive.com</td> </tr> <tr> <td>5</td> <td>Solactive x5 Daily Long JPY and Short USD Index</td> <td>SOJPUS5L</td> <td>Solactive AG</td> <td>DE000SLA6RX6</td> <td>www.solactive.com</td> </tr> <tr> <td>6</td> <td>Solactive x5 Daily Short JPY and Long USD Index</td> <td>SOJPUS5S</td> <td>Solactive AG</td> <td>DE000SLA6RY4</td> <td>www.solactive.com</td> </tr> <tr> <td>7</td> <td>Solactive x3 Daily Long JPY and Short USD Index</td> <td>SOJPUS3L</td> <td>Solactive AG</td> <td>DE000SLA6RV0</td> <td>www.solactive.com</td> </tr> <tr> <td>8</td> <td>Solactive x3 Daily Short JPY and Long USD Index</td> <td>SOJPUS3S</td> <td>Solactive AG</td> <td>DE000SLA6RW8</td> <td>www.solactive.com</td> </tr> <tr> <td>9</td> <td>Solactive X3 Daily Long EUR and Short USD Index</td> <td>SOEUUS3L</td> <td>Solactive AG</td> <td>DE000SLA6RQ0</td> <td>www.solactive.com</td> </tr> </tbody> </table> | Issue | Name of Index | Bloomberg Ticker | Index Sponsor | ISIN code of the Index | Website | 1 | Solactive x5 Daily Long EUR and Short USD Index | SOEUUS5L | Solactive AG | DE000SLA6RS6 | www.solactive.com | 2 | Solactive x5 Daily Short EUR and Long USD Index | SOEUUS5S | Solactive AG | DE000SLA6RU2 | www.solactive.com | 3 | Solactive x5 Daily Long GBP and Short USD Index | SOGBUS5L | Solactive AG | DE000SLA6R16 | www.solactive.com | 4 | Solactive x5 Daily Short GBP and Long USD Index | SOGBUS5S | Solactive AG | DE000SLA6R24 | www.solactive.com | 5 | Solactive x5 Daily Long JPY and Short USD Index | SOJPUS5L | Solactive AG | DE000SLA6RX6 | www.solactive.com | 6 | Solactive x5 Daily Short JPY and Long USD Index | SOJPUS5S | Solactive AG | DE000SLA6RY4 | www.solactive.com | 7 | Solactive x3 Daily Long JPY and Short USD Index | SOJPUS3L | Solactive AG | DE000SLA6RV0 | www.solactive.com | 8 | Solactive x3 Daily Short JPY and Long USD Index | SOJPUS3S | Solactive AG | DE000SLA6RW8 | www.solactive.com | 9 | Solactive X3 Daily Long EUR and Short USD Index | SOEUUS3L | Solactive AG | DE000SLA6RQ0 | www.solactive.com |
| Issue | Name of Index | Bloomberg Ticker | Index Sponsor | ISIN code of the Index | Website | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Solactive x5 Daily Long EUR and Short USD Index | SOEUUS5L | Solactive AG | DE000SLA6RS6 | www.solactive.com | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | Solactive x5 Daily Short EUR and Long USD Index | SOEUUS5S | Solactive AG | DE000SLA6RU2 | www.solactive.com | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | Solactive x5 Daily Long GBP and Short USD Index | SOGBUS5L | Solactive AG | DE000SLA6R16 | www.solactive.com | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4 | Solactive x5 Daily Short GBP and Long USD Index | SOGBUS5S | Solactive AG | DE000SLA6R24 | www.solactive.com | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 5 | Solactive x5 Daily Long JPY and Short USD Index | SOJPUS5L | Solactive AG | DE000SLA6RX6 | www.solactive.com | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6 | Solactive x5 Daily Short JPY and Long USD Index | SOJPUS5S | Solactive AG | DE000SLA6RY4 | www.solactive.com | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 7 | Solactive x3 Daily Long JPY and Short USD Index | SOJPUS3L | Solactive AG | DE000SLA6RV0 | www.solactive.com | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 8 | Solactive x3 Daily Short JPY and Long USD Index | SOJPUS3S | Solactive AG | DE000SLA6RW8 | www.solactive.com | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 9 | Solactive X3 Daily Long EUR and Short USD Index | SOEUUS3L | Solactive AG | DE000SLA6RQ0 | www.solactive.com | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | |
|--|--|----|---|----------|--------------|---------------|--|
| | | 10 | Solactive X3 Daily Short EUR and Long USD Index | SOEUUS3S | Solactive AG | DE000SLA6R R8 | www.solactive.com |
| | | 11 | Solactive x3 Daily Long GBP and Short USD Index | SOGBUS3L | Solactive AG | DE000SLA6R Z1 | www.solactive.com |
| | | 12 | Solactive x3 Daily Short GBP and Long USD Index | SOGBUS3S | Solactive AG | DE000SLA6R 08 | www.solactive.com |

Section D – Risks

| | | |
|-----|--|--|
| D.2 | <p>Key information on the key risks that are specific to the issuer</p> | <p>An investment in the Leveraged Products involves certain risks which should be assessed prior to any investment decision.</p> <p>In particular, the Group is exposed to the risks inherent in its core businesses, including:</p> <ul style="list-style-type: none"> • <u>credit risks:</u> <p>The Group is exposed to counterparty risk and concentration risk.</p> <p>The Group's hedging strategies may not prevent all risk of losses.</p> <p>The Group's results of operations and financial situation could be adversely affected by a significant increase in new provisions or by inadequate provisioning for loan losses.</p> <ul style="list-style-type: none"> • <u>market risks:</u> <p>The global economy and financial markets continue to display high levels of uncertainty, which may materially and adversely affect the Group's business, financial situation and results of operations.</p> <p>The Group's results may be affected by regional market exposures.</p> <p>The Group operates in highly competitive industries, including in its home market.</p> <p>The protracted decline of financial markets may make it harder to sell assets and could lead to material losses.</p> <p>The volatility of the financial markets may cause the Group to suffer significant losses on its trading and investment activities.</p> <p>The financial soundness and conduct of other financial institutions and market participants could adversely affect the Group.</p> |
|-----|--|--|

| | |
|--|--|
| | <p>The Group may generate lower revenues from brokerage and other commission and fee-based businesses during market downturns.</p> <ul style="list-style-type: none"> • <u>operational risks:</u> <p>The Group's risk management system may not be effective and may expose the Group to unidentified or unanticipated risks, which could lead to significant losses.</p> <p>Operational failure, termination or capacity constraints affecting institutions the Group does business with, or failure or breach of the Group's information technology systems, could result in losses.</p> <p>The Group relies on assumptions and estimates which, if incorrect, could have a significant impact on its financial statements.</p> <p>The Group's ability to attract and retain qualified employees is critical to the success of its business, and the failure to do so may materially adversely affect its performance.</p> <p>If the Group makes an acquisition, it may be unable to manage the integration process in a cost-effective manner or achieve the expected benefits.</p> <ul style="list-style-type: none"> • <u>structural interest rate and exchange rate risks:</u> <p>Changes in interest rates may adversely affect the Group's banking and asset management businesses.</p> <p>Fluctuations in exchange rates could adversely affect the Group's results of operations.</p> <ul style="list-style-type: none"> • <u>liquidity risk:</u> <p>The Group depends on access to financing and other sources of liquidity, which may be restricted for reasons beyond its control.</p> <p>A reduced liquidity in financial markets may make it harder to sell assets and could lead to material losses.</p> <ul style="list-style-type: none"> • <u>non-compliance and reputational risks, legal risks:</u> <p>Reputational damage could harm the Group's competitive position.</p> <p>The Group is exposed to legal risks that could negatively affect its financial situation or results of operations.</p> |
|--|--|

| | | |
|-----|--|--|
| | | <p>The Group is subject to an extensive supervisory and regulatory framework in the countries in which it operates and changes in this regulatory framework could have a significant effect on the Group's businesses.</p> <p>A number of exceptional measures taken by governments, central banks and regulators could be amended or terminated, and measures at the European level face implementation risks.</p> <ul style="list-style-type: none"> • <u>other risks:</u> <p>The Group may incur losses as a result of unforeseen or catastrophic events, including the emergence of a pandemic, terrorist attacks or natural disasters.</p> <p>Since the Issuer is part of the Group, these risk factors are applicable to the Issuer.</p> |
| D.6 | <p>Key information on the key risks that are specific to the securities and risk warning to the effect that investors may lose the value of their entire investment or part of it</p> | <p>In the case of Open-ended Leveraged Products, the duration of the Leveraged Products is dependent on an optional early expiration, elected by the Issuer or the Leveraged Product Holder, as the case may be. The possibility of an optional early expiration by the Issuer, on a predetermined date or set of dates, is likely to have a negative effect on the market value of the Leveraged Products. Prospective investors should consider the reinvestment risk in light of other investments available at the time of the expiration. If there is no secondary market, there might be no possibility for the investors to sell the Leveraged Products. Furthermore, this optional early expiration at the sole discretion of the Issuer or the Leveraged Product Holder, as the case may be could prevent the Leveraged Product Holders from benefitting from the performance of the underlying instrument(s) over the whole period initially envisaged.</p> <p>The possibility of an optional early expiration by the Issuer, on a predetermined date, is likely to have a negative effect on the market value of the Leveraged Products. Prospective investors should consider the reinvestment risk in light of other investments available at the time of the early expiration. Furthermore, this optional early expiration at the only discretion of the Issuer could prevent the Leveraged Product Holders from benefitting from the performance of the underlying instrument(s) over the whole period initially envisaged.</p> <p>The Leveraged Products may provide for an event-linked early expiration linked to a specific event. Therefore, this may prevent the Leveraged Product Holders from benefitting from the performance of the underlying instrument(s) over the whole period initially envisaged.</p> <p>The terms and conditions of the Leveraged Products may include provisions under which upon the occurrence of certain market disruptions delays in the settlement of the Leveraged Products may be incurred or certain modifications be made. Moreover, in case of occurrence of events affecting the underlying instrument(s), the terms and conditions of the Leveraged Products allow the Issuer to substitute the underlying instrument(s) by new underlying instrument(s), cease the exposure to the underlying asset(s) and apply a reference rate to the proceeds so obtained until the expiration date of the Leveraged Products, postpone the expiration date of the Leveraged</p> |

Products, cancel the Leveraged Products on the basis of the market value of these Leveraged Products, or deduct from any due amount the increased cost of hedging, and in each case without the consent of the Leveraged Product Holders.

Payments (whether at expiration or otherwise) on the Leveraged Products are calculated by reference to certain underlying(s), the return of the Leveraged Products is based on changes in the value of the underlying(s), which may fluctuate. Prospective investors should be aware that these Leveraged Products may be volatile and that they may receive no return and may lose all or a substantial portion of their investment.

The Guarantees constitute a general and unsecured contractual obligation of the Guarantor and no other person, any payments on the Leveraged Products are also dependent on the creditworthiness of the Guarantor.

Prospective investors in Leveraged Products benefiting from the Guarantees should note that in case of payment default of an Issuer the entitlement of the Leveraged Product Holder will be limited to the sums obtained by making a claim under the Guarantees in accordance with its terms and they shall have no right to institute any proceeding, judicial or otherwise, or otherwise assert a claim against the.

The Guarantees are payment guarantees only and not guarantees of the performance by the relevant Issuer or any of its other obligations under the Leveraged Products benefiting from the Guarantees.

Société Générale will act as issuer under Programme, as the Guarantor of the Leveraged Products issued by the Issuer and also as provider of hedging instruments to the Issuer. As a result, investors will be exposed not only to the credit risk of the Guarantor but also operational risks arising from the lack of independence of the Guarantor, in assuming its duties and obligations as the Guarantor and provider of the hedging instruments.

The potential conflicts of interests and operational risks arising from such lack of independence are in part intended to be mitigated by the fact that different divisions within the Guarantor will be responsible for implementing the Guarantees and providing the hedging instruments and that each division is run as a separate operational unit, segregated by Chinese walls (information barriers) and run by different management teams.

The Issuer and the Guarantor and any of their subsidiaries and/or their affiliates, in connection with their other business activities, may possess or acquire material information about the underlying assets. Such activities and information may cause consequences adverse to Leveraged Product Holders.

The Issuer and the Guarantor and any of their subsidiaries and/or their affiliates may act in other capacities with regard to the Leveraged Products,

such as market maker, calculation agent or agent. Therefore, a potential conflict of interests may arise.

In connection with the offering of the Leveraged Products, the Issuer and the Guarantor and/or their affiliates may enter into one or more hedging transaction(s) with respect to a reference asset(s) or related derivatives, which may affect the market price, liquidity or value of the Leveraged Products.

During the lifetime of the Leveraged Products, the market value of these Leveraged Products may be lower than the invested capital. Furthermore, an insolvency of the Issuer and/or the Guarantor may cause a total loss of the invested capital.

The attention of the investors is drawn to the fact that they could sustain an entire or a partial loss of their investment.

Section E – Offer

| | | |
|--------------|--|---|
| E.2.b | Reasons for the offer and use of proceeds | The net proceeds from each issue of Leveraged Products will be applied for the general financing purposes of the Société Générale Group, which include making a profit. |
|--------------|--|---|

| E.3 | Description of the terms and conditions of the offer | <p>Issue Price:</p> <table border="1"> <thead> <tr> <th data-bbox="609 989 933 1045">Issue</th> <th data-bbox="933 989 1443 1045">Issue Price</th> </tr> </thead> <tbody> <tr><td data-bbox="609 1045 933 1077">1</td><td data-bbox="933 1045 1443 1077">USD 100</td></tr> <tr><td data-bbox="609 1077 933 1108">2</td><td data-bbox="933 1077 1443 1108">USD 100</td></tr> <tr><td data-bbox="609 1108 933 1140">3</td><td data-bbox="933 1108 1443 1140">USD 100</td></tr> <tr><td data-bbox="609 1140 933 1171">4</td><td data-bbox="933 1140 1443 1171">USD 100</td></tr> <tr><td data-bbox="609 1171 933 1203">5</td><td data-bbox="933 1171 1443 1203">USD 100</td></tr> <tr><td data-bbox="609 1203 933 1234">6</td><td data-bbox="933 1203 1443 1234">USD 100</td></tr> <tr><td data-bbox="609 1234 933 1266">7</td><td data-bbox="933 1234 1443 1266">USD 100</td></tr> <tr><td data-bbox="609 1266 933 1297">8</td><td data-bbox="933 1266 1443 1297">USD 100</td></tr> <tr><td data-bbox="609 1297 933 1329">9</td><td data-bbox="933 1297 1443 1329">USD 100</td></tr> <tr><td data-bbox="609 1329 933 1360">10</td><td data-bbox="933 1329 1443 1360">USD 100</td></tr> <tr><td data-bbox="609 1360 933 1392">11</td><td data-bbox="933 1360 1443 1392">USD 100</td></tr> <tr><td data-bbox="609 1392 933 1407">12</td><td data-bbox="933 1392 1443 1407">USD 100</td></tr> </tbody> </table> | Issue | Issue Price | 1 | USD 100 | 2 | USD 100 | 3 | USD 100 | 4 | USD 100 | 5 | USD 100 | 6 | USD 100 | 7 | USD 100 | 8 | USD 100 | 9 | USD 100 | 10 | USD 100 | 11 | USD 100 | 12 | USD 100 |
|------------|---|---|-------|-------------|---|---------|---|---------|---|---------|---|---------|---|---------|---|---------|---|---------|---|---------|---|---------|----|---------|----|---------|----|---------|
| Issue | Issue Price | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | USD 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | USD 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | USD 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4 | USD 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 5 | USD 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6 | USD 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 7 | USD 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 8 | USD 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 9 | USD 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10 | USD 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 11 | USD 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 12 | USD 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Public Offer Jurisdiction(s): United Kingdom.

Offer Period: From 14 March 2018 to the date on which the Leveraged Products are delisted.

Offer Price: The Warrants will be offered at a price which will be determined by Société Générale (the **Dealer**) on the date of sale, such price being calculated by reference to the price at which the Dealer is prepared to sell the Warrants after taking into account such factors as it deems appropriate in connection with the relevant offer which may include (without limitation) market conditions, the terms of the Warrants, the level of subscriptions and macroeconomic conditions (including but not limited to political and economic situations and outlooks, growth rates, inflation, interest rates, credit spread and interest rate spreads)

Conditions to which the offer is subject: None

| | | |
|------------|--|--|
| E.4 | Description of any interest that is material to the issue/offer including conflicting interests | Save for any fees payable to the dealer, so far as the Issuer is aware, no person involved in the issue of the Leveraged Products has an interest material to the offer. |
| E.7 | Estimated expenses charged to the investor by the Issuer or the offeror | Not applicable. No expenses are charged to the investor by the Issuer or the offeror. |

INDEX DISCLAIMER

Solactive is a registered trademark of Solactive AG (the "**Licensor**"). The x5 Daily Long EUR and Short USD Index, x5 Daily Short EUR and Long USD Index, x5 Daily Long GBP and Short USD Index, x5 Daily Short GBP and Long USD Index, x5 Daily Long JPY and Short USD Index, x5 Daily Short JPY and Long USD Index, x3 Daily Long EUR and Short USD Index, x3 Daily Short EUR and Long USD Index, x3 Daily Long GBP and Short USD Index, x3 Daily Short GBP and Long USD Index, x3 Daily Long JPY and Short USD Index AND x3 Daily Short JPY and Long USD Index (each an "**Index**") are calculated and published by the Licensor and have been licensed to Societe Generale for specific purposes.

The financial instruments are not sponsored, promoted, sold or supported in any other manner by Solactive AG (the 'Licensor') nor does the Licensor offer any express or implicit guarantee or assurance either with regard to the results of using each Index and/or Index trade mark or the Index Price at any time or in any other respect. Each Index is calculated and published by the Licensor. The Licensor uses its best efforts to ensure that each Index is calculated correctly. Irrespective of its obligations towards the Issuer, the Licensor has no obligation to point out errors in each Index to third parties including but not limited to investors and/or financial intermediaries of the financial instruments. Neither publication of each relevant Index by the Licensor nor the licensing of each relevant Index or Index trade mark for the purpose of use in connection with the financial instruments constitutes a recommendation by the Licensor to invest capital in said financial instrument nor does it in any way represent an assurance or opinion of the Licensor with regard to any investment in this financial instruments.